141,308 Shares in Diplomat Pharmacy, Inc. (DPLO) Purchased by Vident Investment Advisory LLC
Vident Investment Advisory LLC acquired a new stake in Diplomat Pharmacy, Inc. (NYSE:DPLO) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 141,308 shares of the company’s stock, valued at approximately $2,926,000. Vident Investment Advisory LLC owned approximately 0.21% of Diplomat Pharmacy at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Frontier Capital Management Co. LLC increased its position in shares of Diplomat Pharmacy by 4.1% during the second quarter. Frontier Capital Management Co. LLC now owns 5,677,230 shares of the company’s stock worth $84,023,000 after purchasing an additional 221,769 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Diplomat Pharmacy during the second quarter worth approximately $67,476,000. Vanguard Group Inc. increased its position in shares of Diplomat Pharmacy by 5.4% during the second quarter. Vanguard Group Inc. now owns 4,077,145 shares of the company’s stock worth $60,342,000 after purchasing an additional 210,334 shares in the last quarter. Davis Selected Advisers increased its position in shares of Diplomat Pharmacy by 4.4% during the second quarter. Davis Selected Advisers now owns 1,703,992 shares of the company’s stock worth $25,219,000 after purchasing an additional 71,846 shares in the last quarter. Finally, Cortina Asset Management LLC increased its position in shares of Diplomat Pharmacy by 538.8% during the third quarter. Cortina Asset Management LLC now owns 1,616,792 shares of the company’s stock worth $33,484,000 after purchasing an additional 1,363,696 shares in the last quarter. Institutional investors and hedge funds own 72.48% of the company’s stock.
In other Diplomat Pharmacy news, President Joel Saban purchased 10,000 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were acquired at an average price of $15.24 per share, with a total value of $152,400.00. Following the purchase, the president now directly owns 12,000 shares in the company, valued at approximately $182,880. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Atul Kavthekar purchased 2,000 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief financial officer now owns 2,000 shares in the company, valued at $30,000. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 15,000 shares of company stock worth $228,780. Corporate insiders own 30.20% of the company’s stock.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the prior year, the company posted $0.21 EPS. The company’s quarterly revenue was down 4.8% on a year-over-year basis. sell-side analysts expect that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current year.
Several analysts have issued reports on DPLO shares. Leerink Swann upgraded Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a report on Monday. Deutsche Bank started coverage on Diplomat Pharmacy in a report on Monday, December 4th. They issued a “buy” rating and a $22.00 target price for the company. Robert W. Baird cut Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $24.00 to $18.00 in a report on Thursday, November 16th. BidaskClub cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Finally, Needham & Company LLC upped their target price on Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $20.72.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.watchlistnews.com/141308-shares-in-diplomat-pharmacy-inc-dplo-purchased-by-vident-investment-advisory-llc/1757342.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.